Poolbeg Pharma PLC (AIM: POLB, OTCQB: POLBF) has announced the resignation of Patrick Ashe, an independent director who played a pivotal role in guiding the company through its early stages
Poolbeg Pharma PLC (AIM:POLB) Immunomodulator II patent granted in Japan
Further enhancement of the patent portfolio
Poolbeg Pharma PLC (AIM:POLB) POLB 001 LPS Trial Data to be Presented at IUIS
POLB 001 – a potential blockbuster immunomodulator
Poolbeg Pharma PLC (AIM:POLB) Former Amryt Pharma Leadership Team join Poolbeg
Key Senior Members of Former Amryt Pharma Leadership Team join Poolbeg Pharma Poolbeg team boosted by highly experienced executives with track record of success
Poolbeg Pharma plc (AIM:POLB) POLB 001 Data to be Presented at American Society of Hematology Annual Meeting
Potential to address cancer treatment-related Cytokine Release Syndrome
Poolbeg Pharma PLC (AIM:POLB) POLB 001 Oncology Programme Update Meeting
1 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it will host a meeting for investors
Poolbeg Pharma PLC – SAB Endorses Influenza Drug Targets
Scientific Advisory Board Endorses Influenza Drug Targets Identified in AI Drug Discovery Programme
Poolbeg Pharma PLC (AIM:POLB) Poolbeg Partners with a Nasdaq-Listed Biopharma
Poolbeg Pharma Partners with a Nasdaq-Listed Biopharma Company on its Oral Delivery Platform
Poolbeg Pharma PLC (AIM:POLB) Favourable Conclusion of Patent Opposition
Positive Conclusion Reached in Immunomodulator I Patent Opposition Patent opposition hearing cancelled
Poolbeg Pharma PLC (AIM:POLB) Immunomodulator I Patent Portfolio Strengthened
Notice of allowance for patent grant in Japan
Poolbeg Pharma PLC (AIM:PLOB) Immunomodulator I Patent Opposition Withdrawal
An important step in the continued protection of Poolbeg’s patent family